INTRODUCTION
Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor symptoms including tremor, muscle rigidity, paucity of voluntary movements, and postural instability (Hoehn and Yahr, 1967; Lang and Lozano, 1998) . The pathological hallmarks of PD are the loss of dopaminergic (DAergic) neurons in the substantia nigra pars compacta (SNc) and formation of Lewy bodies (Braak et al., 2003) . The pathogenic process in PD is not clearly understood. A small portion (less than 10%) of PD patients have familial forms of the disease, and several PD genes have been identified (Abou-Sleiman et al., 2006) . However, the vast majority of patients have idiopathic forms of PD. Parkinsonism can be induced in humans by exposure to the mitochondrial complex 1 toxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). This DAergic toxin results in parkinsonism symptoms indistinguishable from those of Parkinson's disease (Burns et al., 1985; Langston et al., 1983) . Experimentally, it induces specific loss of DAergic neurons in the SNc (Burns et al., 1983) and produces a profound reduction of striatal dopamine levels with little alteration in other catecholamine neurotransmitter systems (Jonsson et al., 1986) . Degeneration is a consequence of conversion of MPTP by glia to its toxic metabolite MPP + followed by specific uptake by DAergic neurons and presumed targeting of the mitochondria (Lang and Lozano, 1998) .
The cellular consequences of mitochondrial dysfunction as induced by agents such as MPTP are numerous and include poor calcium homeostasis and oxidative stress (Wang and Yuen, 1994) . How this dysregulation occurs and the consequence/management of these stresses are not fully understood. Recently, and consistent with improper calcium management, we reported that calpains are activated and required for MPTP-induced death in adult mice in vivo . Calpains are conserved cysteine proteases regulated by calcium and possessing diverse biological function (Sorimachi et al., 1997) . This was consistent with earlier reports of elevated calpain levels in postmortem PD patients (Mouatt-Prigent et al., 1996) . We also showed that calpains were more activated in PD patients than in control individuals . Importantly, calpain inhibition not only limited DAergic loss but also improved animal behavior following toxin treatment .
What are the possible downstream targets of calpain activation? We recently provided evidence that the activator of Cdk5, p35, may be critical (Smith et al., , 2006 . Cdk5, not thought to be central to the core cell-cycle machinery, has been implicated in brain function including neuronal development, neuritic outgrowth, and neurotransmitter (dopamine) signaling (Dhavan and Tsai, 2001 ). Cdk5 activity is regulated by its activating partners, p35 and p39 (Dhavan and Tsai, 2001) . While important for brain development, recent evidence has shown that inappropriate activation of the Cdk5/p35 signal may lead to neuronal death through pathogenic activation of calpains, which proteolytically cleave p35 to a more active p25 form (Dhavan and Tsai, 2001 ) at least in cultured systems. However, its functional role in adult degeneration in vivo as well as in PD was unknown. To this end, we found that Cdk5 plays an essential role in DAergic loss in vivo (Smith et al., , 2006 . For example, we observed that MPTP induced Cdk5 activation and that inhibition of such activity with DN Cdk5 expression, Cdk inhibitors, or p35 deficiency attenuated DAergic death and behavioral deficits associated with MPTP treatment (Smith et al., , 2006 . This observation is made more significant by observations of increased p35 in postmortem PD brains (Nakamura et al., 1997) . It is also entirely consistent with our observations that calpains are activated, are required for death, and mediate p35 to p25 cleavage in the MPTP model of PD . In support of this, we showed that inhibition of calpain led to reduced p35 to p25 conversion and Cdk5 activation (Smith et al., 2006) . This suggested to us a model by which deregulated calcium leads to calpain activation, inappropriate Cdk5 activity, and DAergic cell death (Smith et al., 2006) . However, the mechanism(s) by which Cdk5 promotes DAergic loss is still unknown. To address this, we presently performed mass spectrometry-based interactomics to identify Cdk5-interacting proteins. We identified an intriguing target that has direct implications for the way in which cells handle oxidative stress, linking Cdk5 activity with oxidative stress, a common theme in PD.
Oxidative stress is thought to be a critical mediator of damage in PD (Przedborski, 2005) . Reactive oxygen species (ROS) has been observed in the SNc of PD patients and animal models of PD (Przedborski, 2005) . Importantly, neurons in general have high levels of ROS. Therefore, systems to handle such stress are of paramount importance. Peroxidases are a key in this management system. Three types of peroxidases, peroxiredoxins (Prxs), catalase, and glutathione peroxide (GPx), function to eliminate H 2 O 2 in mammalian cells (Rhee et al., 2005) . In mammalian cells, six isoforms of Prx were identified. Although Prxs as a family are relatively ubiquitous, there is some specificity in regards to cell type and subcellular localization. For instance, Prx1 is distributed in the cytoplasm of oligodendrocytes and microglia, while Prx2 is located in the cytoplasm of neurons, and Prx3 is localized in the mitochondria of neurons (Jin et al., 2005) . Whether and how Prxs participate in neuronal damage as well as how they are regulated have yet to be examined.
Presently, we report that Prx2 directly associates with the Cdk5 kinase complex through p35. In addition, Cdk5 phosphorylates Prx2 at T89 resulting in reduction of Prx2 peroxidase activity and neuronal death in MPP + -treated cells in vitro and the MPTP mouse model of PD in vivo. Prx2 activity is functionally relevant since modulation of Prx2 activity is protective. Importantly, p35
À/À neurons have reduced ROS and improved survival consistent with the above findings. These findings provide a mechanistic link of how a mitochondrial damaging agent, through calpain-mediated Cdk5 activation and downregulation of an important antioxidant enzyme, can increase oxidative load leading ultimately to death.
RESULTS

Identification of Prx2 as a Cdk5-Interacting Protein
We have shown that Cdk5 plays an essential role in loss of DAergic neurons in the MPTP mouse model of PD (Smith et al., , 2006 . It has also been demonstrated that Cdk5/p35 exists as macromolecular complexes in brain extracts, implying that Cdk5 associates with different proteins and functions in different signaling pathways (Lee et al., 1996) . To identify these complexes, we initially utilized bacterially expressed GST-p10, a C-terminal truncated form of p35 containing a 98 amino acid residue N terminus fused with GST, as a bait to isolate p35-interacting proteins from mouse brain extracts. The interacting proteins were eluted with 1 M NaCl from GST-immobilized GSH beads. The eluted proteins were visualized by Coomassie blue staining after separation by SDS-PAGE (Figure 1A) . The visualized specific bands were subjected to protein identification by tandem mass spectrometry. One of three specifically isolated proteins was found to be Prx2 for which three identified peptides matches were found ( Figure 1B) .
Prx2 is an antioxidative enzyme with peroxidase activity. Importantly, it also contains a conserved motif optimal for Cdks. Because of these reasons and the potential importance of ROS in PD, we chose this target for our study. To confirm the interaction between p35 and Prx2, an in vitro binding assay was carried out utilizing bacterially expressed proteins. GST-Prx2 or GST alone was incubated with His-tagged p35 and subjected to SDS-PAGE and western blot analyses using p35 antibody. A specific interaction was observed only with GST-Prx2 ( Figure 1C ). Similarly, a reverse binding experiment was performed where GST control or GST-Cdk5 was incubated with His-Prx2 alone or with both His-p35 and His-Prx2. Specific interaction was only observed with GST-Cdk5, His-p35, and His-Prx2 coincubation ( Figure 1C ). Finally, we also examined whether we could detect interaction through a means independent of bacterially expressed proteins by utilizing the yeast two-hybrid interaction assay. Consistent with our previous results, we could also detect interaction between p10 and Prx2 ( Figure S1 available with this article online). These results indicate that Prx2 specifically interacted with the Cdk5/p35 complex through its association with p35.
To test whether endogenous Prx2 may exist in a complex with Cdk5/p35 in vivo, immunoprecipitation was performed using control IgG, , and Cdk5 (C-8) antibodies on brain extracts ( Figure 1D) . The complexes were then analyzed by SDS-PAGE and Western blot analyses using a Prx2 antibody. Both immunoprecipitates using either Cdk5 or p35 antibody showed an associated Prx2 signal by western blot while the control IgG did not. The reverse interaction assay where immunoprecipitation with Prx2 preceded western blot analyses for p35 was also performed using brain extracts. Consistent with the previous pulldown, a specific interaction between Prx2 and p35 was also observed ( Figure 1D ). Finally, to further confirm the specificity of the interaction assay, we also performed a p35 immunoprecipitation using p35 wildtype (WT) or knockout brain extracts followed by western blot analyses utilizing Prx2 antibody. A positive interaction was only observed with WT brain extract and not with p35-deficient brains. Taken together, this indicates that endogenous Prx2 associates with Cdk5/p35 in vivo.
Prx2 Is a Substrate of Cdk5 and Its Peroxidase Activity Is Regulated through Phosphorylation by Cdk5
The consensus sequence of Cdk5 phosphorylation is Pro (P)-directed Ser (S) or Thr (T) surrounded in the +3 position by basic amino acids, Arg (R), Lys (K), or His (H) (Songyang et al., 1996) . There is a potential motif in Prx2 containing Pro-directed Thr, T 89 PRK, optimal for Cdk5 phosphorylation. To investigate whether Prx2 is a substrate of Cdk5, Prx2 and Prx2T89A, a Prx2 mutant in which nonphosphorylatable Ala (A) replaced Thr (T), were subjected to in vitro kinase assay with Cdk5 alone, Cdk5/p35, or Cdk5/p25 active complexes. Incubation of bacterially expressed Prx2 or Prx2T89A with Cdk5 alone did not result in any radiolabel signal, indicating that the activating binding partner of Cdk5 was required for phosphorylation. The recombinant Prx2 was phosphorylated when either p35 or p25 was present along with Cdk5. In contrast, the recombinant Prx2T89A showed almost no detectable phosphorylation ( Figure 2A ). This indicates that both Cdk5/p35 and Cdk5/ p25 can phosphorylate Prx2 and that almost all the phosphorylation occurs on the T89 residue.
To assess the effects of Cdk5-mediated Prx2 phosphorylation on peroxidase activity, WT Prx2 was purified from bacteria. It was then incubated with GST-Cdk5 and GST-p25 purified from bacteria. Afterwards, phosphoPrx2 was separated from nonphosphorylated Prx2 by Q-column. Equal amounts of phosphorylated and nonphosphorylated Prx2 were then assessed for peroxidase activity by monitoring the H 2 O 2 -dependent oxidation of NADPH in the presence of thioredoxin (Trx) and Trx reductase. The peroxidase activity of phospho-Prx2 was 37% of that of nonphosphorylated Prx2 ( Figure 2B ). To confirm isolation and phosphorylation of Prx2 as just described, (B) Identification of Prx2 by a tandem mass spectrometry. The specific bands from GSTp10 were excised from the stained SDS-PAGE for mass spectrometric sequencing. Three underlined peptides were sequenced by the mass spectrometry and matched to mouse Prx2.
(C) Confirmation of the interaction between Prx2 and Cdk5/p35. Two micrograms of bacterially expressed GST and GST-Prx2 was incubated with 10 mg of His-p35 at 4 C for 2 hr.
The GST-tagged proteins were retrieved with GSH beads. The proteins were subjected to SDS-PAGE and detected using C-19 for p35 by western blots (top panel). Similar to the above description, GST was incubated with His-p35 and His-Prx2 or GST-Cdk5 was incubated with His-Prx2 alone or with both His-p35 and His-Prx2 at 4 C for 2 hr. The bound proteins were separated by SDS-PAGE and detected by western blot using anti-Prx2 antibody after retrieval of GST-fused proteins by GSH-Sepharose we generated a phospho-antibody specific for phosphorylated T89 of Prx2. The phospho-T89 (p-T89) antibody recognized phosphorylated Prx2 but not the nonphosphorylated form isolated by Q-column upon western blot analyses ( Figure 2C ). A pan-Prx2 antibody was also isolated and shows that total Prx2 levels were approximately equal between nonphosphorylated and phosphorylated forms ( Figure 2C ). The above results indicate that Cdk5 phosphorylation of Prx2 results in downregulation of peroxidase activity. To confirm this and ascertain that this is due to phosphorylation at T89, we isolated bacterially expressed Prx2, the Prx2T89A mutant, and a Prx2T89E mutant designed to mimic phosphorylation. Equal amounts of proteins were assayed for peroxidase activity. Importantly, the mutant Prx2T89E resulted in a 66% reduction in peroxidase activity compared to Prx2. The mutant Prx2T89A on the other hand was not significantly different from WT ( Figure 2D ). Importantly, we would predict that if Cdk5-mediated phosphorylation of Prx2 at T89 leads to downregulation of peroxidase activity, the Prx2T89A mutant should not be responsive to Cdk5 phosphorylation. Consistent with this notion, phosphorylation of recombinant WT Prx2 but not the Prx2T89A mutant by Cdk5 in vitro led to reduced peroxidase activity ( Figure 2E ). Finally, we also observed that phosphatase treatment of WT Prx2 previously phosphorylated by Cdk5 reversed the decrease in peroxidase (see Figure S2 ). Taken together, our data, at least in vitro, indicate that Cdk5 phosphorylates Prx2 at T89, which results in reduced Prx2 activity.
Prx2 Plays a Protective Role in Cortical Neurons
Insulted by Neurotoxin MPP + We next determined whether Prx2 and its phosphorylation may play a role in neuronal death induced via mitochondrial stress by evaluating the effects of MPP + , the active metabolite of MPTP, on death of cultured cortical neurons. It is important to note that these cultures are completely neuronal as evaluated by MAP2 staining (see Figure S3 ). We first evaluated the effect of MPP + on T89 phosphorylation utilizing the phospho-specific antibody p-T89 for phosphorylated Prx2 at T89. Analysis of an MPP + time course by western blot indicated a maximal increase in phospho-Prx2 signal at 24 hr ( Figure 3A ). This coincided with the peak in Cdk5 kinase activity measured under the same conditions ( Figure 3B ). In the latter assay, immunoprecipitated Cdk5 from neurons treated by MPP + at different time points was subjected to a kinase assay using histone H1 as a substrate. The increase in Prx2 phosphorylation at T89 was also observed in cortical neurons analyzed by immunofluorescence using the same phospho-T89 antibody after MPP + treatment ( Figures 3C, 3D , (B) Peroxidase activity of Prx2 is reduced by phosphorylation. Two hundred micrograms of His-Prx2 was incubated with 10 mg of GSTCdk5/GST-p25 and 10 mM ATP at 30 C for 6 hr. The reaction mixture was separated by Q-column to isolate phospho-Prx2 from Prx2 after clearing GST-tagged Cdk5 and p25 by GSH-Sepharose. 0.5 mg of Prx2 or phosphoPrx2 was used for the peroxidase assay at 30 C for 10 min. The consumption of NADPH was measured at 340 nm wavelength by spectrophotometer. The data are the mean ± SEM (n = 3).
(C) Determination of purity of phospho-Prx2 and confirmation of specificity of p-T89 for phospho-Prx2. One microgram of Prx2 or purified phospho-Prx2 as isolated in (B) was probed by western blot analyses using the p-T89 antibody or a pan-Prx2 antibody.
(D) Peroxidase activity of Prx2T89E is lower than Prx2. 0.5 mg of purified His-Prx2, HisPrx2T89A, or His-PrxT89E was assayed for peroxidase activity as described above in (B). The data is the mean ± SEM (n = 4). (E) Peroxidase activity of Prx2T89A is not affected by Cdk5 phosphorylation. Ten micrograms of purified His-Prx2 or His-Prx2T89A was incubated with or without GST-Cdk5/GST-p25 (3 mg each) overnight at 30 C in the presence of 2 mM DTT. Following dialyses, peroxidase activity was measured as described in (B). The data are the mean ± SEM (n=3).
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Cdk5 Phosphorylation of Prx2 in Neuron Loss and 3E). There was a notable increase in phospho-labeling upon MPP + stress in the soma and neurites. This increase of fluorescence was quantified over a number of neurons by image analyses, showing a 90% increase in neurites and 62% increase in the soma. Blocking peptide treatment was used as a control for specificity and shows the required loss of fluorescent signal. Importantly, levels of Prx2 did not dramatically change upon MPP + treatment. This was observed both with western blot ( Figure 3A ) and upon immunofluorescent analyses ( Figure 3C ). Similar observations of increased phosphorylation of Prx2 were also observed in midbrain cultures containing dopamine neurons exposed to MPP + (see Figure S4 ). In addition, we also observed Prx2 phosphorylation when midbrain neurons were treated with another mitochondrial toxin, rotenone (Greenamyre et al., 2003 ) (see Figure S5 ). We next determined whether a reduction in Prx2 activity accompanied the increase in T89 phosphorylation by analyzing a time course following MPP + treatment of cortical neurons. Importantly, Prx2 activity decreased at 24 hr, opposite to that of T89 Prx2 phosphorylation and Cdk5 activation ( Figure 3F ). These results suggest that Prx2 peroxidase activity is regulated by T89 phosphorylation in cultured neurons following mitochondrial insult.
To evaluate whether T89 phosphorylation of Prx2 plays a role in neuronal death induced by MPP + , cortical neurons were infected with virus expressing Prx2, Prx2T89A, and Prx2T89E. The viability of the infected neurons was assessed by evaluating nuclear integrity after exposing cultures to MPP + for 48 hr. Expression of Prx2 and Prx2T89A significantly protected neurons from death in comparison to that of GFP and Prx2T89E ( Figure 3G ). Conversely, we also evaluated whether downregulation of Prx2 might sensitize neuronal cultures to MPP + treatment. We designed three different siRNA sequences to Prx2. The siRNA sequences 1 and 2 showed the most significant reduction in Prx2 levels ( Figure 3H ). These siRNA sequences sensitized the neuronal cultures to the toxic effects of MPP + treatment ( Figure 3H ). Finally, we also examined for ROS under these conditions by 2 0 , 7'-Dicholororescein diacetate (DCF) staining. As shown in Figure 3I , both siRNA sequences 1 and 2 significantly increased the number of DCF-positive neurons. Taken together, our results suggest a model by which a decrease of Prx2 peroxidase activity mediated through T89 phosphorylation after MPP + insult enhances oxidative stress, resulting in neuronal death.
T89 Phosphorylation of Prx2 Is Mediated by Cdk5 in Neurons after MPP + Treatment
To investigate whether T89 of Prx2 is phosphorylated in neurons by Cdk5, lysates from WT and p35 À/À neurons treated with MPP + were analyzed by western blot. Absence of p35 led to a significant decrease of phosphorylation of Prx2 at T89 ( Figure 4A ). It is important to note, however, that this reduction was not absolute, suggesting that, at least in the present in vitro paradigm, other activators of Cdk5 such as p39 might also be present. It might also be due to the actions of other kinases. Prx2 levels were not observed to vary between WT and p35 À/À neurons with or without MPP + treatment. To further confirm this reduction in phospho-Prx2 signal with p35 deficiency, we carried out immunofluorescent analyses. In p35
neurons, the increase in phospho-T89 signal observed upon MPP + treatment in WT neurons was significantly reduced ( Figure 4B ). Consistent with this observation, similar inhibition of Prx2 phosphorylation was observed with treatment of the Cdk inhibitor Roscovitine, but not with the GSK3 inhibitor lithium (see Figure S6 ). Figure 4C ). This indicates that peroxidase activity of Prx2 is regulated via phosphorylation by Cdk5. These data also suggested that p35 À/À neurons should show reduced oxidative stress and resistance to MPP + -induced neuronal death. To test this, ROS levels were measured utilizing DCF. ROS was significantly increased in WT neurons upon MPP + exposure as measured by both average intensity (54% increase) ( Figures 4E and 4F ) and number of DCF-positive neurons (34% increase) (data not shown). In contrast, p35 À/À neurons showed reduced ROS levels upon MPP + treatment (35% decrease average density, Figure 4F ; 25% decrease total number of cells, data not shown) when compared to WT littermate controls. p35 À/À neurons were also substantially protected from MPP + -induced death when compared to WT littermate control neurons ( Figure 4D ). Finally, based upon our previous observations that calpain-mediated activation of Cdk5 is important for neuronal death (Smith et al., 2006) , we would predict that calpain inhibition should also block Prx2 phosphorylation. Consistent with this, cotreatment of MPP + -exposed neuronal cultures with the calpain inhibitor PD150606 (Sedarous et al., 2003; Wang et al., 1996) led to decreased Prx2 signal as measured by immunofluorescence analyses (Figures 4G and S7) . Taken together, our data indicate that Cdk5 kinase activity has a critical role in the reduction of Prx2 peroxidase activity through phosphorylation of Prx2 at T89 following MPP + insult and that this is a contributing factor to ROS increase and the ensuing neuronal death.
Prx2 Prevents the Loss of DAergic Neurons in the SNc in MPTP Mouse Model of PD
The phosphorylation of Prx2 at T89 by Cdk5 has a functional role in neuronal death in the MPP + -induced cell death model. These data led us to further investigate the effects of Prx2 on neuronal death in an in vivo mouse model of PD. We employed the MPTP mouse model of PD to assess roles of Prx2 in the loss of DAergic neurons. We first determined the effects of expression of WT Prx2 and its mutants, Prx2T89A and Prx2T89E, on survival of DAergic neurons following MPTP administration. These constructs were targeted unilaterally to the SNc DAergic neurons using an adenoviral-mediated gene delivery approach as we have previously performed (Crocker et al., 2001 Kalia et al., 2004; Kim et al., 2005; Smith et al., 2003) . Protein expression of adenoviral Prx2 and its mutant was verified by western blot analysis ( Figure 5B ). We found that expression of Prx2 and Prx2T89A resulted in significant DAergic neuroprotection following MPTP treatment when compared with the contralateral untreated side or with GFP-injected control animals as analyzed by counting the number of tyrosine hydroxylase (TH) positive neurons ( Figures 5A and 5B ). In contrast, expression of Prx2T89E showed similar effects to GFP controls ( Figures 5A and 5B) . As an independent assessment of survival, we also examined for the number of neurons in the SNc region by cresyl violet staining. This also ensures that loss of neurons by MPTP treatment is not simply due to loss of TH expression. Our cresyl violet analysis was similar to that of TH assessment ( Figure 5C ). These data indicate that Prx2 can modulate DAergic neuron survival in the SNc following MPTP administration and suggest that the T89 regulatory site may be important in this DAergic cell death process.
Cdk5-Mediated Phosphorylation of Prx2 at T89 Plays a Pivotal Role in DAergic Neuron Damage by
Regulation of Prx2 Peroxidase Activity in an MPTP Mouse Model of PD The above in vivo evidence only demonstrates that Prx2 could potentially be important in the MPTP model. To further support this, we examined whether endogenous Prx2 may be modulated at T89 following MPTP treatment. Accordingly, the SNc extracts obtained from mice treated with MPTP for various times were subject to western blot analyses. As shown in Figure 6A , Prx2 phosphorylation increased following MPTP treatment, reaching the highest level of phosphorylation at 3 days following injected MPTP. To determine whether the phosphorylation of Prx2 at T89 is mediated by Cdk5, the SNc lysates from p35 À/À mice or WT littermate controls were treated with MPTP and analyzed 3 days post-treatment. The level of phosphorylated Prx2 in p35 À/À mice was significantly less than that in WT mice after MPTP treatment ( Figure 6B ). To further confirm the increase in the level of phosphorylated Prx2 in DAergic neurons in SNc of MPTP-treated mice, we assessed Cdk5-phosphorylated Prx2 by immunofluorescence analyses. Phosphorylated Prx2 was clearly observed in DAergic neurons in the SNc of WT mice treated with MPTP but not substantially observed in that of p35 À/À mice ( Figure 6C ). We quantified the average fluorescent signal from TH-positive neurons by image analyses. As shown in Figure 6D , the fluorescent signal of phospho-Prx2 in WT SNc increased approximately 30%-50% in comparison to untreated WT controls or treated and untreated p35 À/À mice.
To examine whether the peroxidase activity of Prx2 is affected in the MPTP mouse model of PD, Prx2 was isolated from p35 À/À SNc or WT littermate controls with and without MPTP treatment and assayed for activity. Prx2 isolated from WT mice treated by MPTP showed a significant decrease in peroxidase activity in comparison to untreated WT controls. In contrast, p35 À/À animals did not show this reduction following MPTP treatment ( Figure 6E ). Finally, we have previously shown that calpains are central for Cdk5 activation (Smith et al., 2006) . Consistent with this, adenoviral-mediated expression of the calpain inhibitor calpastatin blocks increase in phospho-Prx2 following MPTP treatment in vivo ( Figure S8 ). Taken together, these data indicate that calpain-mediated Cdk5 activation mediates phosphorylation and reduction of Prx2 activity in an in vivo model of PD and that this activity plays an important role in the death of DAergic neurons.
Relevance to Human PD While the above evidence strongly implicates the importance of Prx2 in the MPTP model of PD, we directly examined its potential relevance to human PD. Accordingly, we first examined the phospho-Prx2 signal in human PD postmortem samples and controls. The equivalent T89 site is also present in human Prx2. As shown in Figure 7 , nigral DAergic neurons from human midbrain PD and control samples were clearly detected by the presence of neuromelanin, granular brown pigmented regions detectable even without staining (see arrowheads in Figures 7A and  7B ). When stained using phospho-Prx2 antibody and DAB visualization, little or no signal was detected in the perikarya of dopamine neurons from control midbrain samples. However, significant staining (black color) was observed in soma of dopamine neurons from PD patients (see arrow, Figure 7A ). Staining in the region of neurons that resemble dopamine neurons in size and location but that did not contain neuromelanin was also observed in (G) Prx2 protects neuron form death after MPP + treatment. Cortical neurons were infected with virus expressing GFP alone or along with Prx2, Prx2T89A, or Prx2T89E and cultured for 3 days. The cells were exposed to MPP + for 48 hr and neuronal survival was evaluated by assessing nuclear integrity of GFP-positive neurons. The data are the mean ± SEM (n = 3). Similar results were obtained when equivalent constructs were transfected (data not shown).
(H) Downregulation of Prx2 by siRNA oligonucleotide treatment sensitizes cortical neurons to MPP + treatment. Three independent siRNA sequences (s1/siRNA1, s2/siRNA2, s3/siRNA3) and a control sequence (c/siRNAc) were evaluated for their ability to downregulate endogenous Prx2 levels in cortical neurons as described in Experimental Procedures (top panel). PD samples. Staining of neuritic processes was observed in both control and PD samples. The number of phosphoPrx2-positive dopamine neurons was then quantified from five PD and six control samples. As shown in Figure 7C , a significant increase in phospho-Prx2-positive neurons was observed in PD patient samples when compared to controls. Finally, we examined whether familial PD genes may impact Prx2 phosphorylation. The PD gene, dj-1, has also been linked to management of ROS (Bonifati et al., 2003; Kim et al., 2005) . Interestingly, DJ-1 expression blocked Prx2 phosphorylation in neurons treated with MPP + (Figure S6C) . Modulation of another PD gene, pink1 (Valente et al., 2004) , however, did not affect Prx2 phosphorylation, suggesting some specificity in the way PD genes impact Prx2 phosphorylation ( Figure S6D ). Taken together, our human patient data as well as that with DJ-1 further support the importance of Prx2 in PD.
DISCUSSION
ROS are generated as a result of normal metabolism (Adam-Vizi, 2005) . However, generation of excessive oxidative load beyond a cell's homeostatic capacity can be deleterious. Mitochondrial dysfunction and excess ROS have been strongly implicated in the pathogenesis of PD (Jenner, 1998; Przedborski, 2005) . However, how these events are initiated, are regulated, and interact to promote neuronal death is not completely clear. Recently, we demonstrated that calpain-mediated Cdk5 activation plays an essential role in DAergic loss in the MPTP model of PD Smith et al., 2003 Smith et al., , 2006 . These findings were important since they provided a plausible link between the actions of a mitochondrial damaging agent (MPTP) and activation of a pathogenic calcium-dependent process (calpain activation) consistent with known deregulation of calcium homeostasis in PD. However, the manner by which Cdk5 regulates downstream pathogenic events was not completely known. Presently, we identified a novel Cdk5 target, Prx2, an antioxidant enzyme with peroxidase activity (Rhee et al., 2005) . We provide evidence that Prx2 is a physiological substrate of Cdk5. Cdk5 activation downregulates Prx2 peroxidase activity in PD models of death both in culture and in animals. Modulation of Prx2 activity also regulates neuronal loss. These data provide a mechanistic link of how the mitochondrial damaging agent MPTP leads to nigral loss by Cdk5 activation, phosphorylation/inactivation of an important antioxidant enzyme, and consequent increase in oxidative load (see Figure 8 ). The observation of increased Prx2 phosphorylation in human PD tissue as well as modulation by DJ-1 also indicates the potential importance of this pathway in human PD.
Prx2 Interacts with Cdk5/p35 Complexes and Is a Substrate of Cdk5
Our results demonstrate that Cdk5/p35 interacts with Prx2. Prx2 is a member of the Prx family that contains at least six members. The identification of the Prx2 form as an interacting partner is particularly relevant since Prx2 is localized to neurons, including the DAergic neurons of the SNc (Jin et al., 2005; Sarafian et al., 1998) . This is, in turn, consistent with known DAergic functions of Cdk5, particularly in models of PD as reported previously (Smith et al., , 2006 . In contrast, Prx1, also localized to the cytoplasm, is distributed in oligodendrocytes and microglia (Jin et al., 2005) . These results, particularly in vivo, point to a neuron-specific Cdk5-Prx pathway of ROS management rather than a non-cell-autonomous mode of action regulated by other brain cell types such as glia.
It is important to point out that this does not exclude the potential importance of other Prx members in neuronal loss. For example, Prx3, a mitochondrially localized enzyme (Watabe et al., 1994) , also has potential Cdk5 sites. It will be interesting to determine whether this member might also play a Cdk5-dependent role in mitochondrial stress-induced death.
Our initial results indicated that the N-terminal portion of p35 was sufficient to bind to Prx2. However, it is important to note that both p35 and p25 can efficiently phosphorylate Prx2, at least in vitro. This suggests that stable binding to a Cdk5/p35 complex per se mediated by the p10 fragment is not required for efficient phosphorylation. We speculate that the p10 portion may be an important regulatory domain that regulates how efficiently p35 or Cdk5/p25 complexes may phosphorylate Prx2. Careful analyses will have to be performed to further study this interesting observation. Nonetheless, our results indicate not only that both Cdk5 complexes phosphorylate Prx2 on T89, but also that this modification significantly downregulates its activity.
Under basal conditions, p35 is abundantly localized to the inner cellular membrane, through a myristoylation anchor (Patrick et al., 1999) . Appropriate activation of this form of Cdk5/p35 is the presumptive ''normal'' activity of this complex. However, p35 can be converted to a pathogenic p25 form by calpain-mediated cleavage (Lee et al., 2000; Smith et al., 2003 Smith et al., , 2006 . This results in a more stable active Cdk5 activator as well as the potential to be mislocalized to the nucleus (Gong et al., 2003; O'Hare et al., 2005) . One suggested nuclear target of the Cdk5/p25 complex is Mef2, which we and others have shown is important in models of oxidative stress in vitro (Gong et al., 2003) and following MPTP in vivo (Smith et al., 2006) . Cytoplasmic Cdk5 activity might also be pathogenic. For example, a portion of p25 could also be localized to the cytoplasm, and cytoplasmic targets such as tau have been previously proposed for Cdk5 particularly in models of Alzheimer's disease (Patrick et al., 1999) . In this regard, we have identified an important cytoplasmic target of Cdk5 that could be regulated by either Cdk5/p35 or Cdk5/ p25 complexes. The observation that Cdk5/p25 complexes efficiently phosphorylate Prx2 on T89, however, is consistent with a pathogenic role of this complex.
Cdk5-Mediated Prx2 Downregulation in PD and Oxidative Stress
The identification of Prx2 as a target of Cdk5 is particularly relevant since DAergic neurons are thought to be mice 3 days following MPTP or saline administration were analyzed by western blot analyses using p-T89, anti-Prx2, anti-p35 (C-19), anti-Cdk5 (C-8), and anti-b-actin antibodies. The top panel shows densitometric values of phospho-Prx2 relative to Prx (p-T89/total Prx2*100). Each value is the mean ± SEM (n = 3).
(C) Increased phospho-Prx2 is colocalized with TH-positive neurons. The sections from WT or p35 À/À mice were analyzed 3 days following MPTP or saline treatment. Sections were double-stained using p-T89 antibody (green) and anti-TH monoclonal (red) antibody for 24 hr at 4 C. The sections were incubated with Alex-488-conjugated antibody specific for rabbit IgG and Alex-594-conjugated antibody for mouse IgG for 3 hr at room temperature. The sections were visualized by fluorescent microscopy.
(D) The fluorescent signals from the p-T89 labeling (C) were quantified densitometrically by imaging analysis. Three sets of animals (n = 1 animal/treatment group/set) were individually stained and analyzed by densitometric analyses. 40-50 TH-positive neurons for each animal (over 3-6 slides/ animal) were measured for p-T89 signal. This value was then averaged. Within each set of animals, the average value for each treatment group was normalized to the WT MPTP value. The values were then averaged for all three sets of animals for an n = 3 (mean ± SEM).
(E) Downregulation of peroxidase activity of Prx2 is mediated by Cdk5 in mice administrated by MPTP. Prx2 was isolated from 50 mg of SNc lysates from WT or p35 À/À mice obtained 3 days following treatment with saline, or MPTP was analyzed for peroxidase activity. The data are presented as mean ± SEM (n = 3).
particularly susceptible to oxidative stress (Smythies and Galzigna, 1998) . There are several lines of evidence that support a link between ROS and PD. For example, ROS levels are very high in PD patients (Jenner, 1998; Przedborski, 2005) . Numerous enzymes that produce ROS have been implicated as critical in in vivo models of PD (Przedborski, 2005) . Damaging ROS has also been shown to occur in animals following exposure to mitochondrial poisons (Ara et al., 1998; Schapira, 2001) . Importantly, the mitochondria, a major source of oxidative stress, participates in PD pathogenesis (Przedborski, 2005) . Consistent with this notion, familial forms of PD have been associated with mitochondrial dysfunction. Indeed, the familial PD gene dj-1 is thought to possess direct antioxidant functions (Bonifati et al., 2003; Canet-Aviles et al., 2004; Dawson and Dawson, 2003; Kim et al., 2005; Martinat et al., 2004; Shendelman et al., 2004) . Our evidence suggests that regulation of Prx2 is important in a toxin model of PD. For example, alteration of Prx2 levels modulates death both in vitro and in vivo following MPP + /MPTP. It must be noted, however, that there are limitations to relating the in vivo MPTP model to PD and caution must be observed in making any direct comparisons to the human condition. For example, the relatively acute toxic nature of the MPTP model might not reflect accurately what occurs in the idiopathic PD. Accordingly, to support our MPTP data, we also report that phosphorylation of Prx2 also occurs in the nigral region of PD patients. This is consistent with the relevance of our findings to the human condition. However, standard and important caveats to interpreting any postmortem data apply here as well.
Using the MPTP model as an important first step in understanding the nigral degenerative process, we have identified how Prx2 is modulated to promote death following exposure to this mitochondrial toxin. We have shown previously that Cdk5 is hyperactivated and plays a major functional role in dopamine loss in the MPTP model . It is likely that Cdk5 acts to modify several downstream targets. For example, we had also previously shown that Cdk5 targets the nuclear transcription factor and survival factor Mef2 on a site known to suppress its activity (Smith et al., 2006) . However, cytoplasmic targets may also be critical. We believe that Prx2 is one such important cytoplasmic factor. This is supported by our data showing that Prx2 is phosphorylated at T89 both in vitro and in vivo following MPP + /MPTP and that this is associated with a decrease in peroxidase activity. In support of this, a mutant mimicking constitutively phosphorylated Prx2T89E does not protect neurons from mitochondrial insult, whereas WT or a mutant lacking the T89 phosphorylation site effectively promotes survival. Most importantly, Prx2 phosphorylation is dependent on the Cdk5 complex since p35-deficient animals, which are resistant to death induced by MPP + or MPTP, have reduced Prx2 phosphorylation and Prx2 peroxidase activity. It is important to highlight that, in addition to peroxidase activity, Prx2 is also thought to possess some chaperone activity at least in cell lines . (Yang et al., 2002) . The latter has been also implicated in neuronal death (Bu et al., 2002; Busser et al., 1998; McShea et al., 1997; Nguyen et al., 2003; Osuga et al., 2000; Rashidian et al., 2005; Rideout et al., 2003; Wang et al., 2002; Zhang et al., 2004) . Therefore, whether/how other Prx members are regulated by Cdk members will be of further interest. In summary, we have uncovered an important mechanism by which calpain-mediated Cdk5 activation regulates DAergic neurodegeneration in an MPTP model of PD via downregulation of Prx2 peroxidase activity. We propose that this loss significantly enhances the ROS environment and leads to DAergic neuron loss (Figure 8 ). This central pathway in addition to other pathways mediated by additional calpain or Cdk5 targets ultimately lead to nigral degeneration in response to MPTP (Figure 8 ). These findings are particularly relevant to human PD since both deregulated Cdk5 and increased ROS have been shown in the human PD condition (Jenner, 1998; Nakamura et al., 1997; Przedborski, 2005) . Furthermore, we presently, show that phosphorylated Prx2 is increased in human PD patients and that Prx2 phosphorylation is also modified by dj-1, a known PD gene (Bonifati et al., 2003) . How the latter links to Prx2 phosphorylation will be of great interest in future studies. Taken together, our findings suggest that strategies to modulate Prx2 activity serve as beneficial targets for treatment of PD. This is of particular importance since Cdk5 is thought to have normal beneficial roles in neurons and modulating a relevant downstream target rather than Cdk5 directly may be a better therapeutic strategy with regard to this pathway.
EXPERIMENTAL PROCEDURES
Animals
Eight-week-old male C57BL/6 mice (22-28 g; Charles River Laboratories, USA) were used for MPTP experiments. All animal experiments conformed to the guidelines set forth by the Canadian Council for the Use and Care of Animals in Research (CCAC) and the Canadian Institutes for Health Research (CIHR) and had approval from the University of Ottawa Animal Care Committee.
Antibodies
The following antibodies were utilized: Tyrosine hydroxylase (TH) (Immunostar, USA), C-8 for Cdk5 (Santa Cruz, USA), C-19 for p35 (Santa Cruz, USA), b-Actin (monoclonal, Sigma, Canada), Prx2 (monoclonal, Abcam, UK), and Alex-labeled secondary antibodies (Invitrogen, Canada). Prx2 and phospho-Prx2T89 polyclonal antibodies were generated and initially purified from rabbit using standard protocols from Biogenes (Berlin, Germany) by immunization with carrier protein-conjugated phosphopeptide, LAWINpTPRKEGGLG. The phospho-Prx2 antibody p-T89 was obtained by first purifying the serum using the phosphorylated peptide. The pan-Prx2 antibody was obtained using the nonphosphorylated peptide. The phospho-specific antibody was further purified by adsorbing onto bacterially expressed and purified GST-Prx2 to remove any remaining crossreactivity to nonphosphorylated Prx2. MAP2 was obtained from Santa Cruz (H-300; 1:300).
Isolation of p35-Binding Proteins
The assay was carried out as previously described (Qu et al., 2002) .
Mass Spectrometry
The specific bands on GST-p10 lane were subjected for protein identification by a tandem mass spectrometry as previously described Wilm et al., 1996) .
Fusion Proteins
All GST and His fusion proteins were expressed in E. coli and affinity purified using GSH-beads and Ni-NTA Agarose (QIAGEN Inc, Canada) as per manufacturer's instruction.
In Vitro Binding Assay
The binding assay was performed as previously described (Qu et al., 2002) .
Yeast Two-Hybrid Plasmid construction: Plasmids were constructed using standard subcloning procedures. Briefly, an NcoI/SalI digest of p10 and an NcoI/ BamHI digest of Prx2 were subcloned into NcoI/XhoI-digested pAS2-1 (Clontech, Canada) and Nco/BamHI-digested pACT2 (Clontech), respectively. Yeast two-hybrid screening (Clontech) pAS2-p10 and pACT2-Prx were transformed into Y187 and AH109 strains by the LiAc method (Ito et al., 1993) and plated onto SD-Trp À and SD-Leu À plates, respectively, as previously described (Mao et al., 2004) . Plates were incubated for 5 days at 30 C. Resultant colonies were mated and selected on SD-Leu Immunoprecipitation Samples were harvested in lysis buffer (50 mM Tris-HCl [pH 7.4], 100 mM NaCl, 1 mM EDTA, 1 mM DTT, and 0.2% Triton X-100) supplemented with protease inhibitors. Immunoprecipitations (IPs) were performed through incubation of antibodies with lysates overnight followed by incubation with anti-rabbit or anti-mouse Ig IP beads (eBiosciences, USA) at 4 C for 1 hr. The beads were washed three times by lysis buffer without protease inhibitors.
Neuronal Cultures
The primary culture of mouse cortical neurons was carried out as described previously (Fortin et al., 2001; Xiang et al., 1996) . Alternatively, for midbrain neuronal cultures, the whole midbrain, without meninges and blood vessels, was collected from embryos aged 13.5 days gestation and processed as above and as similarly described (Liu et al., 2000) . Cultures were subject to 20 mM MPP + or rotenone (as indicated in text). In select experiments, neurons were also pretreated with the calpain inhibitor PD150606 (Calbiochem, Canada), the Cdk inhibitor, roscovitine (Sigma, Canada), or lithium (BDH, Canada) for 3 hr and then cotreated with 20 mM MPP + . For survival using p35 À/À neurons, littermate controls, or siRNA knockdowns, the MTT assay was utilized as per manufacturer's instruction (Sigma, Canada). For transfection or infection cultures, the alternative strategy described below was utilized since only a small percentage of the neurons in culture were targeted.
ROS Imaging
Cortical neurons were incubated with 10 mM DCF for 20 min at 37 C and washed three times with NB medium. The fluorescence signal of oxidized DCF was observed by an inverted fluorescent microscope equipped with a 100 W xenon lamp and filter (for oxidized DCF, excitation = 488 nm and emission = 510 nm). At least four random fields were quantified for DCF-positive cells and/or average intensity by image analyses.
Infection and Calcium Phosphate Transfection of Cultured Neurons
Cortical neurons were mixed with adenovirus at MOI of 50 prior to plating and were then immediately seeded to 24-well plates and cultured for three days as previously described (Aleyasin et al., 2004; O'Hare et al., 2005; Zhang et al., 2006) . The cultures were exposed to MPP + for 48 hr. Cultures were then fixed and stained with Hoechst 33258 (0.5 ng/ml) and neuronal survival was evaluated by assessing nuclear integrity of GFP-positive neurons as previously described (Aleyasin et al., 2004) . For transfection, 3 days after plating cortical neurons were transiently transfected using a modified calcium phosphate precipitation protocol (Xia et al., 1996; Zhang et al., 2006) . In brief, neurons were transfected with 1 mg of total plasmid DNA (0.75 mg of plasmid DNA and 0.25 mg of pEGFP as a reporter) purified using an EndoFree Plasmid Maxi kit (QIAGEN, Inc, Canada). Twenty-four hours posttransfection, neurons were treated with 20 mM MPP + (48 hr) and were fixed in 4% paraformaldehyde (containing 0.2% picric acid in 0.1M phosphate buffer [pH 6.9]) and evaluated as described above. Alternatively, neurons were transfected with double-stranded short-interfering RNA (siRNA) to Prx2 or CY3-labeled control duplex (60 pmol siRNA/24-well) as previously described (Zhang et al., 2006) . We have observed that targeting of duplexes to neurons is much more efficient than that of plasmids and have used this procedure previously (Aleyasin et al., 2004; Zhang et al., 2006) . The Prx2 duplexes (s1: GCUUUCG GACUACAGAGGG, s2: GGGAUUCUUUAAGAGCUCU, s3: CCAAAU AAUUACUAGGCCU) along with a Cy3-labeled control duplex were obtained from Ambion (Austin, TX, USA). Forty-eight hours post-transfection, neurons were treated with MPP + (20 mM). At appropriate times, the cells were assayed for survival by MTT method (48 hr) or ROS as described above. Alternatively, cultures were analyzed by Western blot analyses for Prx2 levels (24 hr).
Peroxidase Activity Assay
Peroxidase activity was carried out by measurement of the consumption of NADPH (Fisher) which was mediated by Trx (Sigma, Canada) and Trx reductase (Sigma, Canada) at 30 C for 10 min for bacterially expressed proteins and 1 hr for precipitated proteins from cultured neurons or the SNc. In brief, 0.5 mg of bacterially expressed proteins or the precipitated proteins was incubated with 5 mM Trx, 1 mM Trx reductase, and 100 mM NADPH in HEPES (pH 7.5). The reaction was initiated by the addition of H 2 O 2 at a final concentration of 0.2 mM. The consumption of NADPH was measured at 340 nm by spectrophotometer.
MPTP Administration
Mice received one intraperitoneal (i.p.) injection of MPTP$HCl per day (25 mg of free base per kg of body weight per injection; Sigma) for 3 or 5 consecutive days (Crocker et al., 2001; Kalia et al., 2004; Kim et al., 2005; Smith et al., 2003) ; control mice received an equivalent volume of 0.9% saline. Brains were extracted at indicated times and either perfused for immunohistochemical analyses or quickly removed and dissected for biochemical analyses.
Intrastriatal Administration of Adenoviruses
The adenoviruses expressing Prx2, Prx2T89A, and Prx2T89E were engineered using pAdEasy system as previously described (Sedarous et al., 2003) . We and others have previously shown that adenoviruses can target the SNc from the striatum by retrograde transport (Crocker et al., 2001 Kalia et al., 2004; Kim et al., 2005; Smith et al., 2003) . Each adenovirus was injected directly into the striatum of animals 7 days before initiation of MPTP treatment (as described above). A GFP-containing construct was used as a control. A single unilateral injection of each virus (2 ml, 1 3 10 7 particles per ml) was delivered to the right striatum (0.5 mm rostral, 2.2 mm right of bregma, and 3.4 mm below the skull surface). Each adenovirus injection was given at a constant rate (0.5 ml/min) by using a syringe pump system. Brains were extracted for immunohistochemistry and western blot analysis 14 days after the first MPTP treatment. Double-labeling experiments with GFP (present in all viral vectors) and TH indicated that the majority of SNc TH-positive neurons at the level of the medial terminal nucleus were also GFP positive for all viruses injected (GFP control, Prx2, Prx2T89A, and Prx2T89E).
Immunocytochemistry
Mice were perfused transcardially and brains were fixed in paraformaldehyde and cryoprotected as previously described . Serial coronal sections (14 mm thickness) of the ventral midbrain were collected as free-floating sections in 0.01 M PBS/0.02% sodium azide or collected on slides. Sections were then incubated in primary antibody (to TH, 1:10,000; p-T89, 1:100, in 0.3% Triton X-100/0.01 M PBS) for 24 hr at 4 C. For TH staining on floating sections, slices were then incubated with biotinylated secondary antibody and streptavidin horseradish peroxidase-conjugated tertiary antibody and visualized by using a 3,3 0 -diaminobenzidine/glucose oxidase reaction as previously described . To examine the distribution of phosphorylated Prx2 in DAergic neurons, a double-labeling immunofluorescence approach was used. After incubation with the specific primary antibody at 4 C, immunolabeling was visualized by using either Alex-488-conjugated anti-rabbit IgG (1:2000) or Alex-594-conjugated anti-mouse IgG (1:2000).
Quantification of DAergic Neuron Loss
The number of DAergic (TH-positive) neurons was only counted from the sections in the region containing the medial terminal nucleus (MTN) because this region has been previously shown to be expressed at the highest level of virus-mediated gene expression after intrastriatal infection (Crocker et al., 2001) . We also used the MTN as a landmark to evaluate consistent levels of the SNc. Neurons ipsilateral and contralateral to the viral injection were assessed as described above in at least three sections per animal. The number of neurons from ipsilateral or contralateral was then counted as previously described. Alternatively, cresyl violet staining was performed to validate determination of nigral counts as previously described .
Western Blot Analysis for the SNc
The western blot assay was performed as previously described . In brief, 50 mg of protein was analyzed by SDS-PAGE using antibodies to phospho-Prx2T89, Prx2, and b-actin.
Human Brain Samples
Paraffin-embedded blocks of postmortem human midbrain were collected from the Ottawa Hospital Department of Pathology. Autopsies were performed according to the policies and procedures of The Ottawa Hospital with consent from the next-of-kin. The tissue was deparaffinized in xylene and subjected to citrate antigen retrieval (Martins et al., 1999) prior to DAB staining. Diagnoses of PD were made based on medical histories and postmortem confirmation (J.M.W.).
The mean average age for PD (n = 5; 4 males and 1 female) and control patients (n = 6; 6 males) was 72.6 ± 3.7 and 72.5 ± 3.6, respectively, and showed no significance (p < 0.986). Postmortem intervals for PD and control samples did not differ significantly (p < 0.3).
Supplemental Data
The Supplemental Data for this article can be found online at http:// www.neuron.org/cgi/content/full/55/1/37/DC1/.
